Bungowannah Virus
LEVELS: Highly unlikely; No human illness; Extraordinary biosecurity required; No validated assay; Moderate; Negligible; Little; Available, or not needed
| Register id | bungowannah_virus |
| Type | virus |
| Scientific name | Porcine pestivirus isolate Bungowannah |
| NCBI taxid | 412969 |
| Evidence | 2 document(s) |
| Assigned | 2026-09-06, against criteria version 093366e352a2 |
Overview
Bungowannah virus is a pestivirus known from a single large Australian pig complex, where it caused porcine myocarditis syndrome. The outbreak was severe: preweaning mortality reached 50% at its peak, 40% of fetuses were stillborn and 13% mummified in some units, and across a 30,000-sow complex an estimated 50,000 pigs were lost over fifteen months. The damage is done entirely before birth — infection of pigs after birth produces almost no clinical effect regardless of dose — and once the virus becomes endemic and animals are infected before their first breeding, the disease may disappear from view while transmission continues. Persistently infected pigs are immunotolerant, mostly fail to make antibody, and shed large amounts of virus; viral RNA was found in the semen of about 20% of boars even when their antibody titres were high. It is unusually elusive: it is not detected by diagnostic assays once believed to react with every pestivirus, and it does not damage cells in culture, so demonstrating that it has grown requires staining. Limited surveys in Germany and the US Midwest have not found it. There is no treatment and no commercial vaccine, but a renewed eradication attempt succeeded in 2022 using partial depopulation plus an autogenous live vaccine in replacement gilts.
C1 Zoonotic potential
Likelihood of transmission from pigs to humans
Highly unlikely: Human infection with the agent has never been reported, or has been reported but is not attributed to pig or pork exposure
Basis. ch35 35.1.1, which is the whole of the chapter's public health section and covers every entry in this batch: "There is no evidence of human infection with pestivirus, and they are not of any significance for public health or food safety." shic_2011_appv: "There is no evidence that pestiviruses, including APPV, are zoonotic."
How this level was decided
Level 1, stated outright for the whole genus. Confirmed. The statement is made of the pestiviruses as a group, which reaches Bungowannah.
C2 Zoonotic impact
Severity of human illness caused by the agent
No human illness: Agent does not cause illness in people
Basis. ch35 35.1.1, which is the whole of the chapter's public health section and covers every entry in this batch: "There is no evidence of human infection with pestivirus, and they are not of any significance for public health or food safety." shic_2011_appv: "There is no evidence that pestiviruses, including APPV, are zoonotic."
How this level was decided
Level 1. No human infection with pestiviruses is on record. Confirmed on the same group statement.
C3 Herd introduction risk
Effort required to keep the agent out of the herd
Extraordinary biosecurity required: Exclusion needs measures beyond the routine, such as air filtration, thermally treated feed and bedding, or repeated costly testing to find carriers, and may still fail
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED at level 4 on the C3 review sheet. "l4, but only because we still have uncertainty about how it incurred and transmitted in AU"
Basis. ch35 35.3.3: "Reintroduction was thought to have occurred via aerosols generated during decontamination of an infected module 0.5-1.5 km away from the Bungowannah virus-free unit." "Bungowannah virus RNA has been detected in the semen of approximately 20% of boars at the time of initial screening, despite high serum neutralizing antibody titers." 35.3.4: persistently infected animals "were immunotolerant and most failed to mount a humoral immune response". 35.3.3: "Due to the large amount of virus shed into the environment by persistently infected pigs, postnatal transmission presumably occurs following oronasal exposure." 35.3.1: "The natural hosts of Bungowannah virus... remain to be determined." shic_2011_appv: "an atypical pestivirus causing reproductive loss and high mortality in weaners emerged in Australia in 2003. Bungowannah virus was only distantly related to other pestiviruses, with the greatest similarity to a pronghorn antelope isolate. Bungowannah virus has not occurred outside of Australia." On the pestiviruses generally: "Pestiviruses are able to avoid immune detection and establish persistent infection (PI)... The viral proteins Npro and Erns, which are necessary for establishing PI, are found in all pestiviruses."
How this level was decided
Level 4. There is no known reservoir outside pigs -- the natural host is unknown and no wildlife or vector cycle has ever been shown -- so this is not level 5. But two of the routes named in the level 4 label are documented here in their worst form. Carriers are immunotolerant and antibody-negative, so serology finds nothing and detection needs repeated PCR; and a fifth of boars had viral RNA in semen DESPITE high neutralising antibody titres, which means the obvious screening test does not clear them. Add aerosol transmission over 0.5 to 1.5 km during a decontamination, and exclusion plainly needs more than the routine and may still fail. The chapter proves the last clause: an eradication attempt at the larger site in 2009-2010 failed outright. Level 4 confirmed, and the new source supplies the mechanism the level turns on. Exclusion of a pestivirus is a carrier problem: persistently infected animals are the reservoir, they are immunotolerant so serology misses them, and the route in is live pigs and semen rather than anything a barn wall stops. That is repeated costly testing to find carriers, which is the level 4 list.
C4 Detection difficulty
Difficulty of recognizing and confirming infection
No validated assay: No pathogen-specific test of known reliability exists anywhere, and identification depends on sequencing or on primers that have not been critically evaluated
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED after being flagged. "c4l4, the evidence about validated tests for this virus are unconvincing, no surprise because only one country, on one farm, has seen the virus, keep at l4." The cell was put to him because the SHIC APPV factsheet describes a "Pan-pestivirus RT-PCR for CSFV, BVDV-1, BVDV-2, BDV, Bungowannah virus, and APPV" -- the first assay of any kind in that folder that names the agent. His answer is the 2026-08-29 C4 rework applied: the axis is whether a VALIDATED assay exists, and an agent seen on one farm in one country has nothing against which an assay could have been validated.
Basis. ch35 35.3.1: "It is of concern that this virus is not detected by diagnostic assays once thought to react with all members of the genus Pestivirus." 35.3.7: "the clinical presentation has similarities to in utero infection with CSFV, BVDV, and BDV and with late onset CSF." "the virus is not cytopathic in cell culture; thus, immunoperoxidase staining is required to verify virus replication in cell cultures." 35.3.3: it has been sought and not found in Germany and the upper Midwestern United States, "but only very limited surveys have been conducted". shic_2011_appv notes a "Pan-pestivirus RT-PCR for CSFV, BVDV-1, BVDV-2, BDV, Bungowannah virus, and APPV."
How this level was decided
Level 4, the framework's worked example at that level, and the chapter states the level 4 test as a stated concern rather than an inference: the pan-pestivirus assays that were believed to catch everything in the genus do not catch this virus. So an outbreak in a country that has never seen it would return negative on the screening test and be worked up as a low-virulence CSFV or a BVDV until someone sequenced it. The clinical picture points at three other pestiviruses instead of at this one, and the reference assays that do exist are held in one Australian laboratory. LEVEL 4 HELD, BUT FLAGGED, because this is the first assay of any kind in the folder that names Bungowannah. A described pan-pestivirus multiplex is not the same as a validated Bungowannah assay available to a US laboratory, and the 2026-08-29 C4 rework exists precisely because the pass had been reading a published primer set as a validated assay and moved three entries L3 -> L4 for it. Applying that rule, this stays at 4. If Eric reads a pan-pestivirus multiplex in routine use as validated coverage, it is a 3.
C5 Production cost
Financial impact on the infected farm's cost of production
Moderate: Losses measurably increase cost of production but remain manageable within normal farm operations, whether acute, chronic, or associated with endemic disease
Basis. ch35 35.3.5: "At the peak of the outbreak, preweaning mortality reached 50%, 40% of fetuses were stillborn, and 13% were mummified in some production units. In a combined herd consisting of approximately 30,000 sows, it is estimated that 50,000 pigs were lost from production due to porcine myocarditis syndrome over a 15-month period." "Postnatal infection with Bungowannah virus is associated with few clinical effects." "Once the virus becomes endemic in a population, if animals are infected prior to first breeding, clinical disease may not be recognized despite ongoing transmission." shic_2011_appv: Bungowannah is "an atypical pestivirus causing reproductive loss and high mortality in weaners".
How this level was decided
Level 3. The peak figures are severe -- half the piglets dying before weaning in some units -- but the herd-level arithmetic is what the criterion asks for: 50,000 pigs lost from a 30,000-sow herd over fifteen months is on the order of five percent of production, and the business kept operating throughout and eventually eradicated the virus. Losses that measurably increase cost of production but remain manageable within normal farm operations. It is not level 4, because nothing here threatened the enterprise, and the chapter notes that once the virus goes endemic and gilts meet it before breeding the clinical disease may not even be recognised. Level 3 confirmed. The new source is terse but names both halves of the loss -- reproductive failure and weaner mortality -- which is measurable and manageable rather than short-lived.
C6 Market impact
Duration of material disruption to pork and pig markets
Negligible: Little or no material disruption to supply or demand when disease occurs on one or more farms
Basis. ch35 35.3.3 and 35.3.5 describe a real outbreak on two Australian farms with 50,000 pigs lost over 15 months, an eradication attempt that failed in 2009-2010 and a successful one in 2022. No trade measure, movement control or consumer response is recorded anywhere in section 35.3. Bungowannah is not a WOAH-listed disease.
How this level was decided
Level 1, and this is the first application of the rule added to SCORING/market_impact on 2026-09-02. The test is not whether the agent is exotic but whether anything has ever been observed -- and here something was. A substantial outbreak ran for fifteen months on a 30,000-sow complex in a developed pig industry, was investigated, published and eradicated, and produced no market consequence the chapter thought worth recording. That is an observed precedent of no reaction, which is scoreable, unlike dengue where nothing has ever happened at all. Unchanged. The factsheet adds nothing on markets beyond confining the virus to Australia.
C7 Treatment potential
Potential for treatment to improve outcomes
Little: Effective pathogen-directed treatment is available and works, or animals recover acceptably without it
Basis. ch35 35.3.9: "There is no specific treatment for porcine myocarditis syndrome or commercial vaccine against Bungowannah virus." 35.3.4: "Unlike CSFV, there appears to be no appreciable clinical effects following postnatal infection with Bungowannah virus, regardless of the dose of virus. Thus, disease appears to be wholly the result of in utero infection of the fetus." shic_2011_appv: "There is no treatment for APPV infection in swine. Experimentally, some pestiviruses are inhibited by the aromatic cationic compound DB772."
How this level was decided
Level 1 on the second clause, and the chapter's own pathogenesis section is the argument. The pig that could be treated is not the pig that is harmed: postnatal infection produces no appreciable clinical effect at any dose, and the damage is done in utero before anything is recognised. A pathogen-directed treatment has nothing to act on. Under the standing note SCORING/treatment_potential there is no imperative to treat. Unchanged. Noted for the record that a pestivirus inhibitor exists experimentally, which is a research lead rather than a treatment.
C8 Vaccine availability
Availability of effective vaccines or bacterins
Available, or not needed: Effective vaccines are widely available in the US or secured for national outbreak response, or the disease does not clinically or economically justify vaccinating
Basis. ch35 35.3.9: "There is no specific treatment for porcine myocarditis syndrome or commercial vaccine against Bungowannah virus." 35.3.3: "A renewed attempt to eradicate the virus from this large farm complex was successful in 2022 after partial depopulation and vaccination of all replacement breeding females with an autogenous live vaccine prior to breeding."
How this level was decided
Level 1 on the second clause of the reworded criterion. No commercial vaccine exists and none is warranted: the virus has only ever been found on two related Australian farms, both of which are now free of it, and it has been sought without success in Germany and the US Midwest. What the chapter also shows is that the absence is one of demand rather than of capability -- when a vaccine was actually needed, an autogenous live product was made and it worked, forming part of the successful 2022 eradication. Unchanged. The factsheet reports no Bungowannah vaccine and says cross-protection between pestiviruses is unlikely given their genetic variability.
Levels and evidence are generated from data/assignments/bungowannah_virus.yml; the overview is authored in data/overviews/bungowannah_virus.md. Do not hand-edit this page — corrections go in data/assignments/CORRECTIONS.yml.
Quoted material marked Basis is from Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J, eds. Diseases of Swine, 12th edition. Hoboken: Wiley Blackwell, 2025 — except where another source is named in the quotation itself.